Federal Circuit Affirms Apple Watch Import Ban: The Full Story of Apple vs. Masimo

Federal Circuit Affirms ITC’s Import Ban: What the March 2026 Decision Means

On March 19, 2026, the U.S. Court of Appeals for the Federal Circuit issued a unanimous decision affirming the International Trade Commission’s (ITC) determination that Apple infringed Masimo’s blood oxygen measurement patents in violation of Section 337 of the Tariff Act. The ruling upheld a limited exclusion order (LEO) that bars importation of specific Apple Watch models incorporating the infringing technology. The underlying ITC investigation, designated as 337-TA-1276, concerns “Certain Light-Based Physiological Measurement Devices and Components Thereof.”

The foundation for this case traces back to June 2021, when Masimo Corporation and Cercacor Laboratories filed their ITC complaint just nine months after Apple launched the Apple Watch Series 6 with blood oxygen measurement capabilities in September 2020. The complaint alleged that Apple’s implementation of SpO2 (oxygen saturation) measurement directly infringed Masimo’s patented technology, triggering one of the most significant IP disputes in wearable medical device technology.

The Patents at Issue and Technical Infringement

The legal dispute centers on Masimo’s portfolio of patents collectively known as the “Poeze Patents.” The patents in question—U.S. Patent Nos. 10,912,501, 10,912,502, 10,945,648, 10,687,745, and 7,761,127—cover wearable light-emitting diode (LED) and photodetector-based SpO2 measurement systems. These patents represent decades of innovation in optical sensing technology adapted for consumer wearable devices, a domain where Masimo holds significant technological leadership as a medical device pioneer.

The Federal Circuit specifically affirmed infringement across four independent claims spanning two of the Poeze Patents: U.S. Patent Nos. 10,912,502 and 10,945,648. These claims directly cover the technical architecture Apple incorporated into the Apple Watch Series 6 through Series 8—specifically the combination of on-device LED arrays with photodetector sensors configured to measure blood oxygen levels through reflectance spectrophotometry. Apple mounted multiple challenges to the ITC’s infringement finding, including arguments regarding claim construction, patent validity, domestic industry requirements, and prosecution laches (unreasonable delay). The Federal Circuit rejected all of these challenges, providing a decisive victory for Masimo.

The Same-Day Design-Around Approval: A Crucial Procedural Development

On the identical date as the Federal Circuit’s affirmation—March 19, 2026—a separate ruling emerged from the ITC that shifted the practical landscape. ALJ Monica Bhattacharyya approved Apple’s redesigned blood oxygen measurement system, finding that the modified implementation does not infringe Masimo’s patents.

Apple’s design-around strategy demonstrates a crucial principle in ITC enforcement: the import ban targets specific technical implementations, not functional capabilities. Under Apple’s revised approach, blood oxygen sensor data is still collected by the Apple Watch hardware, but the measurement processing and analysis occur on the paired iPhone. Users access blood oxygen results through the iPhone app rather than viewing them directly on the watch display. Apple developed this workaround in August 2025 and had refined it sufficiently by November 2025 to support implementation, demonstrating that device redesign represents a viable alternative to continued litigation.

This dual determination illustrates how ITC limited exclusion orders function as a policy tool. Rather than eliminating product categories from the market, LEOs target particular technical implementations and force companies to pursue alternative architectures. The original Apple Watch design remains subject to the import ban, while the iPhone-processing variant is legally permissible, creating clear incentives for technological innovation in service of patent respect.

The Parallel 4 Million Jury Verdict: Economic Reinforcement

While the ITC proceedings unfolded, parallel civil litigation in federal district court reached its own conclusion. In November 2025, a federal jury determined that Apple owes Masimo $634 million in damages for patent infringement. This monetary judgment, combined with the import restriction, created a two-pronged enforcement mechanism against continued use of the original design.

The significance of the $634 million verdict extends beyond its face value as economic compensation. It represents the jury’s assessment of damages accrued from the period of infringing sales, establishing a financial disincentive for maintaining the original technical architecture. For Apple, this judgment meant that regulatory import restrictions alone were insufficient to constrain the business incentive to defend the existing design; the combination of trade remedies and monetary damages created compounding pressure for strategic realignment.

ITC as Strategic Leverage: The Masimo Playbook

Masimo Corporation, founded in 1989, established itself as a pioneer in pulse oximetry and noninvasive monitoring technology. The company accumulated decades of R&D investment in optical measurement science before Apple’s consumer market entry with blood oxygen features. From Masimo’s perspective, Apple’s rapid implementation of SpO2 measurement in a mass-market product without licensing represented not merely a competitive threat but a direct appropriation of hard-won technical knowledge.

The case exemplifies a critical strategic advantage available to smaller technology companies facing larger incumbents: the ITC provides specialized procedures and remedies tailored to import-based infringement. Unlike domestic patent litigation, which typically concludes with damages awards, ITC enforcement operates through border exclusion—a remedy with immediate market consequences. Masimo’s decision to pursue the ITC route, initiating the complaint nine months after Apple Watch Series 6 launched, reflected calculated strategy. The medical device company recognized that the ITC’s statutory mandate to protect domestic industry (a status Masimo clearly occupied through manufacturing and R&D in the United States) provided faster, more decisive remedies than conventional patent litigation alone.

The Timeline: From Launch to Affirmation

Understanding this dispute requires examining its chronological development. Apple launched the Apple Watch Series 6 with blood oxygen measurement in September 2020. Masimo filed its ITC complaint in June 2021—a nine-month window that appears calculated: sufficient time to establish market presence and technical viability, but short enough to address the infringement before the design became entrenched across multiple watch generations. The ITC investigation then proceeded through the standard discovery and litigation phases, culminating in the March 19, 2026 dual determinations. The November 2025 jury verdict preceded the Federal Circuit affirmation by approximately four months, establishing financial liability before the appellate court’s technical confirmation.

Apple’s parallel development of the design-around (August 2025) and refinement through November 2025 suggests the company anticipated the adverse Federal Circuit decision. By March 2026, Apple possessed both a validated alternative implementation and clear guidance that the original approach remained indefensible. This timeline illustrates how larger companies, despite their litigation resources, cannot indefinitely maintain infringing designs once the ITC identifies clear violations—the combination of trade remedies and damage liability forces technical pivots even when companies possess sophisticated legal arguments.

Legal Analysis: Claims Construction and Validity Questions

The Federal Circuit’s affirmation encompassed several legally significant determinations. First, the court upheld the ITC’s claim construction—its interpretation of what the patent language actually covers. Apple had argued that the patent claims should be read narrowly, excluding the specific technical approach Apple employed. The Federal Circuit disagreed, confirming that Masimo’s claims reach Apple’s on-device processing architecture. This construction victory prevents Apple from designing around the patents through semantic arguments about claim scope.

Second, the court rejected Apple’s patent validity challenges. Apple raised conventional arguments: that the patents lacked adequate written description, that they were anticipated by prior art, or that they were obvious in light of the existing optical measurement literature. The Federal Circuit found these arguments insufficiently supported. Masimo’s patents survived scrutiny under the Patent Trial and Appeal Board (PTAB) standards and appellate review, confirming their fundamental validity.

Third, the court addressed domestic industry—a Section 337 requirement that the complainant must establish a domestic industry exploiting the patent. Masimo satisfied this requirement through its own manufacturing and development of blood oxygen measurement technology, even though Masimo did not directly compete in the consumer smartwatch market. The Federal Circuit confirmed that the domestic industry analysis encompasses the relevant technology (optical SpO2 measurement) rather than requiring head-to-head product competition.

Strategic Implications for IP Enforcement in Medical Technology

This case establishes several lasting principles for IP enforcement strategy in medical device technology. First, the ITC remains a viable forum for smaller companies to enforce patents against larger manufacturers when domestic industry requirements are satisfied. Masimo’s victory demonstrates that company size and litigation resources are not determinative of ITC outcomes when technical infringement is clear.

Second, design-arounds represent a realistic alternative to indefinite litigation. Apple’s successful implementation of the iPhone-processing variant shows that technical problems can be solved through architectural redesign rather than continued infringement. For patent holders, this implies that ITC victories may be partial rather than total exclusions—the import ban restricts specific implementations but does not necessarily eliminate the accused product category.

Third, the combination of ITC remedies with civil damages creates more powerful enforcement than either mechanism alone. The import restriction removes immediate incentive to maintain the infringing design, while the monetary judgment eliminates backward-looking profit. Companies facing this combination face both forward and backward economic pressure to align with patent requirements.

Conclusion: Medical Technology Patents and Consumer Electronics

The Federal Circuit’s March 2026 affirmation of the ITC’s limited exclusion order against Apple represents a significant confirmation of patent protection in medical device technology, even when that technology is integrated into consumer electronics. Masimo’s litigation strategy—pursuing ITC enforcement based on clear infringement of optical measurement patents—generated outcomes that reshape Apple’s product architecture and establish precedent for future medical technology disputes involving wearable devices.

The case demonstrates that the ITC framework, despite its specialized procedures and narrower remedies than district court patent litigation, provides effective enforcement tools for companies with established domestic industry. For Apple, the combination of the import ban, the $634 million jury verdict, and the practical limitations of defending an infringing design created sufficient pressure to pursue technical redesign. For Masimo and other medical technology companies, the decision confirms that ITC proceedings offer strategic advantages when formal patent infringement is established and domestic industry requirements are met.